Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud
| Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud |
| Autore | Vergnaud Jean-Maurice |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Boca Raton, FL : , : CRC Press, , 1993 |
| Descrizione fisica | xii, 410 p. : ill |
| Disciplina | 615/.6 |
| Collana | Ellis Horwood series in pharmaceutical technology |
| Soggetto topico | Oral medication |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-429-18086-1
1-4822-6735-7 0-203-99989-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1 Mathematical treatment of diffusion: the plane dosage forms; cylinder of finite length; spherical dosage forms. Part 2 Numerical analysis for diffusion: plane dosage forms; cylinder of finite length; spherical dosage forms; other shapes; one or two matter transfers; models taking into account the swelling of the polymer matrix. Part 3 Description of various oral dosage forms: drug dispersed in a non-erodible polymer matrix, plane, spherical; drug dispersed in an erodible polymer matrix; dosage forms made of a core and shell, with an erodible shell; dosage forms made of a core and shell, with a non-erodible shell; dosage forms able to deliver the drug when the solubility of the drug is very low; problem of drying dosage forms made of drug and polymer. |
| Record Nr. | UNINA-9910449829103321 |
Vergnaud Jean-Maurice
|
||
| Boca Raton, FL : , : CRC Press, , 1993 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud
| Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud |
| Autore | Vergnaud Jean-Maurice |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Boca Raton, FL : , : CRC Press, , 1993 |
| Descrizione fisica | xii, 410 p. : ill |
| Disciplina | 615/.6 |
| Collana | Ellis Horwood series in pharmaceutical technology |
| Soggetto topico | Oral medication |
| ISBN |
0-429-18086-1
1-4822-6735-7 0-203-99989-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1 Mathematical treatment of diffusion: the plane dosage forms; cylinder of finite length; spherical dosage forms. Part 2 Numerical analysis for diffusion: plane dosage forms; cylinder of finite length; spherical dosage forms; other shapes; one or two matter transfers; models taking into account the swelling of the polymer matrix. Part 3 Description of various oral dosage forms: drug dispersed in a non-erodible polymer matrix, plane, spherical; drug dispersed in an erodible polymer matrix; dosage forms made of a core and shell, with an erodible shell; dosage forms made of a core and shell, with a non-erodible shell; dosage forms able to deliver the drug when the solubility of the drug is very low; problem of drying dosage forms made of drug and polymer. |
| Record Nr. | UNINA-9910777072803321 |
|
Vergnaud Jean-Maurice
|
||
| Boca Raton, FL : , : CRC Press, , 1993 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud
| Controlled Drug Release Of Oral Dosage Forms / / Jean-Maurice Vergnaud |
| Autore | Vergnaud Jean-Maurice |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Boca Raton, FL : , : CRC Press, , 1993 |
| Descrizione fisica | xii, 410 p. : ill |
| Disciplina | 615/.6 |
| Collana | Ellis Horwood series in pharmaceutical technology |
| Soggetto topico | Oral medication |
| ISBN |
0-429-18086-1
1-4822-6735-7 0-203-99989-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1 Mathematical treatment of diffusion: the plane dosage forms; cylinder of finite length; spherical dosage forms. Part 2 Numerical analysis for diffusion: plane dosage forms; cylinder of finite length; spherical dosage forms; other shapes; one or two matter transfers; models taking into account the swelling of the polymer matrix. Part 3 Description of various oral dosage forms: drug dispersed in a non-erodible polymer matrix, plane, spherical; drug dispersed in an erodible polymer matrix; dosage forms made of a core and shell, with an erodible shell; dosage forms made of a core and shell, with a non-erodible shell; dosage forms able to deliver the drug when the solubility of the drug is very low; problem of drying dosage forms made of drug and polymer. |
| Record Nr. | UNINA-9910819729803321 |
|
Vergnaud Jean-Maurice
|
||
| Boca Raton, FL : , : CRC Press, , 1993 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The family physician, and the house apothecary [[electronic resource] ] : containing I. Medicines against all such diseases people usually advise with apothecaries to be cured of, II. Instructions, whereby to prepare at your own houses all kinds of necessary medicines that are prepared by apothecaries, or prescribed by physicians, III. The exact prices of all drugs, herbs, seeds, simple and compound medicines, as they are sold at the druggists, or may be sold by the apothecaries, IV. That it's plainly made to appear, that in preparing medicines thus at your own houses, that it's not onely a far safer way, but you shall also save nineteen shillings in twenty, comparing it with the extravagant rates of many apothecaries / / by Gideon Harvey .
| The family physician, and the house apothecary [[electronic resource] ] : containing I. Medicines against all such diseases people usually advise with apothecaries to be cured of, II. Instructions, whereby to prepare at your own houses all kinds of necessary medicines that are prepared by apothecaries, or prescribed by physicians, III. The exact prices of all drugs, herbs, seeds, simple and compound medicines, as they are sold at the druggists, or may be sold by the apothecaries, IV. That it's plainly made to appear, that in preparing medicines thus at your own houses, that it's not onely a far safer way, but you shall also save nineteen shillings in twenty, comparing it with the extravagant rates of many apothecaries / / by Gideon Harvey . |
| Autore | Harvey Gideon <1640?-1700?> |
| Pubbl/distr/stampa | [London?], : Printed for T.R. and are to be sold by the booksellers of London, M DC LXXVI [1676] |
| Descrizione fisica | [24], 165 [i.e. 167], [4] p |
| Soggetto topico |
Oral medication
Pharmacy |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996386863903316 |
|
Harvey Gideon <1640?-1700?>
|
||
| [London?], : Printed for T.R. and are to be sold by the booksellers of London, M DC LXXVI [1676] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
The family-physician, and the house-apothecary [[electronic resource] ] : containing I. Medicines against all such diseases people usually advise with apothecaries to be cured of, II. Instructions, whereby to prepare at your own houses all kinds of necessary medicines that are prepared by apothecaries, or prescribed by physicians, III. The exact prices of all drugs, herbs, seeds, simple and compound medicines, as they are sold at the druggists, or may be sold by the apothecaries, IV. That it's plainly made to appear, that in preparing medicines thus at your own houses, that it's not onely a far safer way, but you shall also save nineteen shillings in twenty, comparing it with the extravagant rates of many apothecaries / / by Gideon Harvey .
| The family-physician, and the house-apothecary [[electronic resource] ] : containing I. Medicines against all such diseases people usually advise with apothecaries to be cured of, II. Instructions, whereby to prepare at your own houses all kinds of necessary medicines that are prepared by apothecaries, or prescribed by physicians, III. The exact prices of all drugs, herbs, seeds, simple and compound medicines, as they are sold at the druggists, or may be sold by the apothecaries, IV. That it's plainly made to appear, that in preparing medicines thus at your own houses, that it's not onely a far safer way, but you shall also save nineteen shillings in twenty, comparing it with the extravagant rates of many apothecaries / / by Gideon Harvey . |
| Autore | Harvey Gideon <1640?-1700?> |
| Edizione | [The second edition, revised by the author.] |
| Pubbl/distr/stampa | [London], : Printed for M.R. ..., 1678 |
| Descrizione fisica | [24], 165 [i.e. 167] p |
| Soggetto topico |
Oral medication
Pharmacy |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996385469903316 |
|
Harvey Gideon <1640?-1700?>
|
||
| [London], : Printed for M.R. ..., 1678 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Formulation and analytical development for low-dose oral drug products [[electronic resource] /] / edited by Jack Zheng
| Formulation and analytical development for low-dose oral drug products [[electronic resource] /] / edited by Jack Zheng |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (492 p.) |
| Disciplina | 615/.1 |
| Altri autori (Persone) | ZhengJack |
| Soggetto topico |
Drugs - Dose-response relationship
Drugs - Dosage Oral medication Drug development |
| ISBN |
1-282-03105-8
9786612031052 0-470-38636-3 0-470-38635-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
An overview / Jack Y. Zheng -- Challenges and strategies in formulation development of oral solid low-dose drug products / Jack Y. Zheng -- Particle size of drug substance and product content uniformity: theoretical considerations / Kevin C. Johnson -- Development of low-dose formulations using fluidized bed granulation / J. Joe Zhou, and Ralph Lipp -- Development of low-dose solid oral formulations using wet granulation / Ahmad Almaya -- Challenges in development and scale-up of low dose drug products by dry granulation: a case study / Mary T. Am Ende ... [et al.] -- Development of low-dose solid oral tablets using direct compression / Jack Y. Zheng and Robert L. Ternik -- Reduction of particle size of drug substance for low-dose drug products / Christopher L. Burcham ... [et al.] -- Function, quality, and regulations of pharmaceutical excipients for oral solid dosage forms / Jack Y. Zheng --
Analytical method development: challenges and solutions for low-dose oral dosage forms / Beverly Nickerson ... [et al.] -- In vitro dissolution testing and method development / Vivian A. Gray, Jack Y. Zheng, and Norman N. Sesi -- Analysis of physical transformation of API during manufacture and storage / Gregory A. Stephenson -- Physical characterization tests for drug substances used in low-dose formulations / Ronald G. Lacocca -- An excipient library approach to analytical development for low-dose, solid oral dosage form drug products / Qing Chang ... [et al.] -- Cleaning verification for highly potent compounds / Brian W. Pack -- Containment challenges and strategies for potent compounds in the pharmaceutical industry / Victoria Cathcart, Sarah Jones, Beverly Nickerson -- Sample handling and containment in analytical testing laboratories / David Pattavina, Nancy Sage, Beverly Nickerson -- Regulatory considerations in the development of low-dose solid oral drug products / Ravi S. Harapanhalli. |
| Record Nr. | UNINA-9910146149903321 |
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Formulation and analytical development for low-dose oral drug products [[electronic resource] /] / edited by Jack Zheng
| Formulation and analytical development for low-dose oral drug products [[electronic resource] /] / edited by Jack Zheng |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (492 p.) |
| Disciplina | 615/.1 |
| Altri autori (Persone) | ZhengJack |
| Soggetto topico |
Drugs - Dose-response relationship
Drugs - Dosage Oral medication Drug development |
| ISBN |
1-282-03105-8
9786612031052 0-470-38636-3 0-470-38635-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
An overview / Jack Y. Zheng -- Challenges and strategies in formulation development of oral solid low-dose drug products / Jack Y. Zheng -- Particle size of drug substance and product content uniformity: theoretical considerations / Kevin C. Johnson -- Development of low-dose formulations using fluidized bed granulation / J. Joe Zhou, and Ralph Lipp -- Development of low-dose solid oral formulations using wet granulation / Ahmad Almaya -- Challenges in development and scale-up of low dose drug products by dry granulation: a case study / Mary T. Am Ende ... [et al.] -- Development of low-dose solid oral tablets using direct compression / Jack Y. Zheng and Robert L. Ternik -- Reduction of particle size of drug substance for low-dose drug products / Christopher L. Burcham ... [et al.] -- Function, quality, and regulations of pharmaceutical excipients for oral solid dosage forms / Jack Y. Zheng --
Analytical method development: challenges and solutions for low-dose oral dosage forms / Beverly Nickerson ... [et al.] -- In vitro dissolution testing and method development / Vivian A. Gray, Jack Y. Zheng, and Norman N. Sesi -- Analysis of physical transformation of API during manufacture and storage / Gregory A. Stephenson -- Physical characterization tests for drug substances used in low-dose formulations / Ronald G. Lacocca -- An excipient library approach to analytical development for low-dose, solid oral dosage form drug products / Qing Chang ... [et al.] -- Cleaning verification for highly potent compounds / Brian W. Pack -- Containment challenges and strategies for potent compounds in the pharmaceutical industry / Victoria Cathcart, Sarah Jones, Beverly Nickerson -- Sample handling and containment in analytical testing laboratories / David Pattavina, Nancy Sage, Beverly Nickerson -- Regulatory considerations in the development of low-dose solid oral drug products / Ravi S. Harapanhalli. |
| Record Nr. | UNINA-9910825789603321 |
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Mixing Tamiflu® with sweet liquids [[electronic resource]]
| Mixing Tamiflu® with sweet liquids [[electronic resource]] |
| Pubbl/distr/stampa | Atlanta, GA : , : Centers for Disease Control and Prevention, , [2009] |
| Soggetto topico |
Antiviral agents
Pediatric oral medicine Oral medication Capsules (Pharmacy) Drugs - Solubility Influenza - Treatment Swine influenza - Treatment |
| Soggetto genere / forma |
Documentary films.
Streaming videos. |
| Formato | Videoregistrazioni  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910699216903321 |
| Atlanta, GA : , : Centers for Disease Control and Prevention, , [2009] | ||
| Videoregistrazioni | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oral controlled release formulation design and drug delivery : theory to practice / / edited by Hong Wen, Kinam Park
| Oral controlled release formulation design and drug delivery : theory to practice / / edited by Hong Wen, Kinam Park |
| Pubbl/distr/stampa | Hoboken, NJ : , : Wiley, , 2010 |
| Descrizione fisica | 1 online resource (x, 363 pages) : illustrations |
| Disciplina | 615/.6 |
| Altri autori (Persone) |
WenHong <1967->
ParkKinam |
| Soggetto topico |
Drugs - Controlled release
Oral medication |
| ISBN |
1-118-06032-6
1-282-77297-X 9786612772979 0-470-64048-0 0-470-64047-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ORAL CONTROLLED RELEASE FORMULATION DESIGN AND DRUG DELIVERY: Theory to Practice; CONTENTS; PREFACE; CONTRIBUTORS; 1 INTRODUCTION AND OVERVIEW OF ORAL CONTROLLED RELEASE FORMULATION DESIGN; 2 EVOLUTION OF ORAL CONTROLLED RELEASE DOSAGE FORMS; 3 BIOPHARMACEUTIC CONSIDERATION AND ASSESSMENT FOR ORAL CONTROLLED RELEASE FORMULATIONS; 4 PREFORMULATION CONSIDERATION FOR DRUGS IN ORAL CR FORMULATION; 5 POLYMERS IN ORAL MODIFIED RELEASE SYSTEMS; 6 ORAL EXTENDED RELEASE HYDROPHILIC MATRICES: FORMULATION AND DESIGN; 7 COATING SYSTEMS FOR ORAL CONTROLLED RELEASE FORMULATIONS
8 FLUID BED COATING AND GRANULATION FOR CR DELIVERY; 9 CONTROLLED RELEASE USING BILAYER OSMOTIC TABLET TECHNOLOGY: REDUCING THEORY TO PRACTICE; 10 FAST DISINTEGRATING TABLETS; 11 BUCCAL DRUG DELIVERY SYSTEMS; 12 ORAL TARGETED DRUG DELIVERY SYSTEMS: GASTRIC RETENTION DEVICES; 13 ORAL TARGETED DRUG DELIVERY SYSTEMS: ENTERIC COATING; 14 ORALLY ADMINISTERED DRUG DELIVERY SYSTEMS TO THE COLON; 15 DISSOLUTION TESTING: IN VITRO CHARACTERIZATION OF ORAL CONTROLLED RELEASE DOSAGE FORMS; 16 CHALLENGES AND NEW TECHNOLOGIES OF ORAL CONTROLLED RELEASE 17 ORAL CONTROLLED DRUG DELIVERY: QUALITY BY DESIGN (QbD) Approach to Drug Development; 18 ORAL CONTROLLED RELEASE-BASED PRODUCTS FOR LIFE CYCLE MANAGEMENT; 19 GENERIC ORAL CONTROLLED RELEASE PRODUCT DEVELOPMENT: FORMULATION AND PROCESS CONSIDERATIONS; 20 THE SCIENCE AND REGULATORY PERSPECTIVES OF EMERGING CONTROLLED RELEASE DOSAGE FORMS; INDEX |
| Record Nr. | UNINA-9910140803603321 |
| Hoboken, NJ : , : Wiley, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oral drug delivery for modified release formulations / / edited by Edmund S. Kostewicz [and three others]
| Oral drug delivery for modified release formulations / / edited by Edmund S. Kostewicz [and three others] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , [2022] |
| Descrizione fisica | 1 online resource (491 pages) |
| Disciplina | 615.6 |
| Soggetto topico |
Oral medication
Drug delivery systems Controlled release preparations |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-119-77272-9
1-119-77270-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Preface -- List of Contributors -- Part I Understanding of Physiology and Anatomy - Factors Influencing Drug Release and Absorption from MR Formulations -- Chapter 1a Composition of Gastric Fluids Under Fasting and Fed Conditions -- 1a.1 Gastric Volume -- 1a.2 Gastric Acid -- 1a.3 Buffer Capacity -- 1a.4 Mucus/Viscosity -- 1a.5 Enzymes -- 1a.6 Surface Tension -- 1a.7 Osmolality -- 1a.8 Duodenogastric Reflux -- References -- Chapter 1b Composition of the Small Intestinal Contents Under Fasting and Fed Conditions -- 1b.1 Small Intestinal Volume -- 1b.2 pH Profile Along the Small Intestine -- 1b.3 Composition of the Luminal Contents -- 1b.3.1 Bile -- 1b.3.2 Phospholipids -- 1b.3.3 Monoglycerides and Free Fatty Acids -- 1b.4 Other Characteristics of Small Intestinal Fluids -- 1b.4.1 Buffer Capacity -- 1b.4.2 Osmolality -- 1b.4.3 Surface Tension -- 1b.4.4 Ionic Strength -- 1b.4.5 Viscosity -- 1b.5 Influence of Age, Gender, and Disease on the Small Intestinal Composition -- References -- Chapter 1c The Luminal Environment in the Proximal Colon -- 1c.1 Volume of Luminal Contents -- 1c.1.1 Liquid Contents -- 1c.1.2 Aspirated Contents and Liquid Fractions -- 1c.2 Luminal pH Values -- 1c.2.1 Data Collected with Telemetric Capsules -- 1c.2.2 Data Collected with Aspirated Samples -- 1c.3 Buffer Capacity -- 1c.4 Characteristics of Liquid Fraction of Contents -- 1c.5 Concluding Remarks -- References -- Chapter 2 Gastrointestinal Transit and Hydrodynamics Under Fasting and Fed Conditions -- 2.1 Introduction -- 2.2 Imaging Techniques Used for Assessment of Transit Times and Hydrodynamics -- 2.3 Oral Cavity and Esophagus -- 2.4 Stomach -- 2.5 Small Intestine -- 2.6 Large Intestine -- 2.7 Whole Gut Transit Time -- 2.8 Therapy-Related Effects on GI Transit.
2.9 Motility Disorders Affecting the GI Transit of Oral Dosage Forms -- 2.10 Patient-Related Effects on GI Transit -- 2.10.1 Age -- 2.10.2 Gender -- 2.10.3 Dietary and Smoking Habits -- 2.11 Conclusion -- References -- Chapter 3 Intestinal Epithelium and Drug Transporters -- 3.1 Introduction: Oral Drug Absorption General Mechanisms and Influencing Factors -- 3.2 Expression of Drug Transporters in the Intestinal Epithelium -- 3.3 Uptake Transporters Present at the Intestinal Level -- 3.4 Regional Distribution of Uptake Transporters -- 3.5 Efflux Transporters at the Intestinal Level -- 3.6 Regional Distribution of Efflux Transporters -- 3.7 Impact of the Regional Distribution of Enzymes and Transporters in the Intestine on the Enzyme/Transporter Interplay -- 3.8 Species Differences in Regional Expression of Uptake and Efflux Transporters -- 3.9 Models for Regional Assessment of Intestinal Permeability -- 3.10 Use of PBPK to Integrate Formulation and Permeation Knowledge -- 3.11 Impact of Regional Solubility and Permeability Along the Intestine -- 3.12 Formulation Excipients and Their Potential Modulatory Effects on Transporters -- 3.13 Other Confounding Factors Affecting Drug Intestinal Absorption -- 3.14 Drug-Drug Interactions -- 3.15 Conclusion and Future Challenges -- References -- Chapter 4 The Interplay Between Drug Release and Intestinal Gut-Wall Metabolism -- 4.1 The Role of Gut Wall Metabolism in Determining Oral Bioavailability -- 4.1.1 Cytochrome P450's (CYPs) -- 4.1.2 Uridine 5-Diphosphate Glucuronosyltransferases (UGTs) -- 4.1.3 Sulfotransferases (SULTs) -- 4.1.4 Other Drug-Metabolizing Enzymes in the Gut-Wall -- 4.1.5 Luminal Degradation in the Gut -- 4.2 Factors Affecting Gut Wall Metabolism -- 4.2.1 Absorption -- 4.2.2 Mucosal Blood Flow -- 4.2.3 Protein Binding -- 4.2.4 Metabolic Drug-Drug Interactions. 4.2.5 Intestinal Transporter-Metabolism Interplay -- 4.3 Preclinical and Clinical In Vivo and In Situ Models for Studying Intestinal Metabolism -- 4.4 In Vitro Assays for Studying Intestinal Metabolism -- 4.5 Models for Studying Bacterial Degradation -- 4.6 In Vitro-In Vivo Extrapolation of Metabolic Clearance and In Silico Models for Predicting In Vivo Gut Wall Metabolism -- 4.7 Oral Extended-Release Formulations and Gut Wall Metabolism -- 4.8 Excipient Effects on Gut Wall Metabolism -- 4.9 Considerations for Intestinal Metabolism in Special Populations -- 4.10 Summary -- References -- Part II Design of MR Formulations - Considerations, Mechanisms and Technologies -- Chapter 5 Preformulation Considerations for Design of Oral Modified-Release Products -- 5.1 Introduction -- 5.2 Purpose of MR Formulations -- 5.3 Means to Obtain MR Drug Products -- 5.3.1 Physicochemical Characterization of the Drug Substance and its Impact on the Design of Modified-release Dosage Forms -- 5.4 Ionization Constant - pKa -- 5.5 Lipophilicity -- 5.6 Solubility -- 5.7 Chemical Stability -- 5.8 Solid State Characterization -- 5.9 Compatibility with Excipients -- 5.10 Permeability and Metabolism -- 5.10.1 Additional Early Drug Substance Testing -- 5.11 Regional Absorption -- 5.12 Microbial Stability -- 5.12.1 Early Performance Testing of Formulations -- 5.13 Quality by Design (QbD) for MR formulations -- 5.14 Conclusions -- References -- Chapter 6 The Application of Biopharmaceutics Classification Systems to Modified-Release Formulations -- 6.1 Introduction -- 6.2 The Use of Biopharmaceutics Classification Systems in Oral Drug Development -- 6.3 The Application of Classification Systems to MR Drug Product Development - An Evidence-Based Approach -- 6.3.1 Test Sets Used. 6.3.2 Where Do Successfully Marketed Modified-Release Products Fit in Solubility/Permeability Classification Systems? -- 6.3.3 Classification System Categorization and Relative Colonic Bioavailability Data -- 6.3.4 The Significance of Dissolution Rate and Solubility in the Colon -- 6.3.5 Does Ionization State Matter? -- 6.3.6 Managing Low Solubility (DCS IIA/IIB) -- 6.3.7 Managing Low Permeability (DCS III/IV) -- 6.3.8 Beyond Permeability and Solubility: Other Factors Affecting MR Feasibility -- 6.3.8.1 Time-period for Drug Release and Absorption -- 6.3.8.2 Bacterial Metabolism in the Colon -- 6.3.8.3 Uptake Transporters -- 6.3.8.4 Gut Wall First-Pass Metabolism -- 6.3.8.5 Efflux Transporters -- 6.3.9 Relative Bioavailability in the Colon (FrelColon) as a Guide to Extended-Release Formulation Feasibility -- 6.3.10 The Properties of Drugs for Delayed-Release (Gastro Protection) -- 6.3.11 The Properties of Drugs for Targeting Local Release in the Lower GI Tract -- 6.4 Summary -- References -- Chapter 7 Technologies and Mechanisms for Oral Modified Release by Monolithic and Multiparticulate Delivery Systems -- 7.1 Introduction -- 7.2 Mechanism of Drug Release -- 7.3 Manufacturing Processes -- 7.3.1 Pelletization Processes -- 7.3.1.1 Extrusion-spheronization -- 7.3.1.2 Layering Techniques -- 7.3.1.3 Direct Pelletization from Powders (Wet Granulation) -- 7.3.2 Particulate Production from Liquid Systems (Globulation Methods) -- 7.3.2.1 Pelletization Methods Utilizing Melts -- 7.3.2.2 Spray Drying and Spray Congealing -- 7.3.2.3 Jet Cutting (Prilling) -- 7.3.3 Compression Methods -- 7.4 Formulation Screening and Characterization -- 7.5 Conclusions and Perspectives -- References -- Chapter 8 Lipid-based Formulations -- 8.1 Introduction -- 8.2 Mechanisms of Lipid-mediated Improvements in Bioavailability. 8.2.1 Increased Drug Solubilization and Dissolution in the GIT -- 8.2.2 Increased Intestinal Permeability, Reduced First-pass Metabolism, and Intestinal Efflux -- 8.2.3 Promotion of Intestinal Lipid Absorption and Lymphatic Uptake -- 8.3 Lipid-based Formulations for Controlled Release -- 8.3.1 Solid Lipid Excipient Matrices -- 8.3.2 Solid Lipid Nanoparticles -- 8.4 Design of Lipid-based Formulations -- 8.4.1 Excipient Type and Selection -- 8.4.2 Drug Loading -- 8.4.3 Formulation Types and the Lipid Formulation Classification System -- 8.5 Formulation Screening and Characterization -- 8.5.1 Drug Solubility in Lipid-based Formulations -- 8.5.2 Self-emulsification and the Effect of Dispersion -- 8.5.3 Impact of Digestion -- 8.5.4 Assessing Supersaturation and Precipitation -- 8.5.5 Identifying Formulation Limiting Factors and the Lipid Formulation Performance Classification System (LF-PCS) -- 8.5.6 Characterization of Nanoparticulate Lipid-based Formulations -- 8.5.7 Preclinical to Clinical Dose Scaling and Developing In Vitro and In Vivo Correlations -- 8.6 Industrial Considerations on LBF -- 8.7 Emerging Applications of Lipid-based Formulations -- 8.8 Conclusions -- References -- Chapter 9 Strategies for MR Formulation Development: Mesoporous Silica -- 9.1 Introduction -- 9.2 Technologies -- 9.2.1 The Template Method in Synthesis of Mesoporous Silica -- 9.2.1.1 M41S Mesoporous Materials -- 9.2.1.2 SBA Mesoporous Materials -- 9.2.2 Factors Affecting Drug Loading -- 9.3 Characterization -- 9.4 Stability of Drug Carrier -- 9.5 Silica-based Materials for the Modified Release of Poorly Soluble Drugs - In Vitro/In Vivo Applications -- 9.5.1 pH-sensitive Silica-based Systems -- 9.5.2 Surface-modification of Silica-based Materials -- 9.5.3 Lipid Formulations of Silica-based Materials -- 9.6 Toxicological Assessment -- 9.6.1 In vitro Toxicity. 9.7 Conclusions and Future Directions. |
| Record Nr. | UNINA-9910566692103321 |
| Hoboken, New Jersey : , : Wiley, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
